Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinoma

Trial Profile

Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2015 Status changed from recruiting to discontinued, as reported by University Hospital Medical Information Network - Japan record.
    • 11 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top